《大行報告》富瑞下調港交所(00388.HK)目標價至373.94元 評級「持有」
富瑞發表報告指,港交所(00388.HK)去年利潤為125億元,低於市場預測的129億元,主要是受到去年第四季交易額疲弱影響。
該行表示,由於俄羅斯與烏克蘭衝突,港交所股價於2月24日下跌了5.4%,但相信對集團的長遠營運影響有限,較大的下行壓力反而可能來自跌至長期趨勢的日均成交額。另外,港交所在吸引優質企業/投資者以改善流動性方面仍面對挑戰
富瑞下調港交所股份目標價,由459.67元降至373.94元,評級維持「持有」,並因應日均成交額下跌而調低集團今明兩年盈利預測。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.